GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered for use in infants and children aged ≥6 weeks.

DTPa-hepB-IPV-Hib — diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccine

The vaccine consists of both a 0.5 mL monodose pre-filled syringe and a vial containing a lyophilised pellet.

The pre-filled syringe contains:

  • ≥30 IU diphtheria toxoid
  • ≥40 IU tetanus toxoid
  • 25 µg pertussis toxoid
  • 25 µg filamentous haemagglutinin
  • 8 µg pertactin
  • 10 µg recombinant hepatitis B surface antigen (HBsAg)
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)

Adsorbed onto aluminium hydroxide/phosphate.

Also contains traces of:

  • formaldehyde
  • polysorbate 80
  • polysorbate 20
  • polymyxin
  • neomycin

The vial containing a lyophilised pellet contains:

  • 10 µg purified Hib capsular polysaccharide conjugated to 20–40 µg tetanus toxoid

May contain yeast proteins.

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018


diphtheria-tetanus-acellular pertussis vaccine
inactivated poliomyelitis vaccine
international units
hepatitis B surface antigen